Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of LBL-033 in the Treatment of Patients With Advanced Malignant Tumors.

NCT05779163 is registered in ClinicalTrials.gov with Nanjing Leads Biolabs Co.,Ltd as lead sponsor.

NCT NCT05779163
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05779163 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of LBL-033 in the Treatment of Patients With Advanced Malignant Tumors.
Lead sponsor
Nanjing Leads Biolabs Co.,Ltd
Phase
Phase 1/2
Overall status
Completed
Start date
April 14, 2023
Completion date
April 3, 2025
Enrollment
26 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant tumors